Synagis injection: reconstitution no longer required

Synagis (palivizumab), AbbVie's respiratory syncytial virus (RSV) prophylactic for use in high-risk infants and children under two years, has been reformulated and is now available as a solution for injection.

Further information
View Synagis drug record
Summary of Product Characteristics
Manufacturer: AbbVie

The licensed indications, dosing, contraindications and warnings for use, and safety profile for the solution are identical to that of the lyophilised powder formulation which has now been discontinued.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.